company background image

AbbVieNYSE:ABBV Stock Report

Last Price


Market Cap







19 Jan, 2022


Company Financials +
ABBV fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance2/6
Financial Health3/6

ABBV Stock Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.

AbbVie Competitors




Gilead Sciences



Regeneron Pharmaceuticals



Horizon Therapeutics



Price History & Performance

Summary of all time highs, changes and price drops for AbbVie
Historical stock prices
Current Share PriceUS$135.21
52 Week HighUS$138.15
52 Week LowUS$101.81
1 Month Change3.32%
3 Month Change24.32%
1 Year Change20.06%
3 Year Change52.87%
5 Year Change120.28%
Change since IPO286.31%

Recent News & Updates

Jan 15

AbbVie Will Keep Going Higher

AbbVie continues to be under-appreciated and undervalued. The company's revenue, EPS, and dividend arc all consistent growers. Shares appear capable of appreciating 20-30% this year.

Jan 06

AbbVie: Doing The RIG(HT) Thing

Aside of performance and volatility, proper diversification and proper allocation/s are crucial. Don't bet too much on anything, no matter how "sexy" it may look. RIG's largest position has a 5.2% allocation and it's up 16.5% over the past six weeks (since inception date). At the same time, RIG's best/worst position is up/down 26.8%/18.3%. Luckily, allocation to the best is 6.5x bigger than allocation to the worst.

Shareholder Returns

ABBVUS BiotechsUS Market

Return vs Industry: ABBV exceeded the US Biotechs industry which returned -18.4% over the past year.

Return vs Market: ABBV exceeded the US Market which returned 10.2% over the past year.

Price Volatility

Is ABBV's price volatile compared to industry and market?
ABBV volatility
ABBV Average Weekly Movement2.6%
Biotechs Industry Average Movement10.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: ABBV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.

About the Company

201250,000Rick Gonzalez

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.

AbbVie Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
ABBV fundamental statistics
Market CapUS$239.04b
Earnings (TTM)US$7.47b
Revenue (TTM)US$55.17b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABBV income statement (TTM)
Cost of RevenueUS$16.44b
Gross ProfitUS$38.73b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 02, 2022

Earnings per share (EPS)4.22
Gross Margin70.19%
Net Profit Margin13.53%
Debt/Equity Ratio594.7%

How did ABBV perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is AbbVie undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ABBV ($135.21) is trading below our estimate of fair value ($308.63)

Significantly Below Fair Value: ABBV is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: ABBV is poor value based on its PE Ratio (32x) compared to the US Biotechs industry average (23.5x).

PE vs Market: ABBV is poor value based on its PE Ratio (32x) compared to the US market (17x).

Price to Earnings Growth Ratio

PEG Ratio: ABBV is poor value based on its PEG Ratio (7.4x)

Price to Book Ratio

PB vs Industry: ABBV is overvalued based on its PB Ratio (17.6x) compared to the US Biotechs industry average (2.1x).

Future Growth

How is AbbVie forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABBV's forecast earnings growth (4.3% per year) is above the savings rate (2%).

Earnings vs Market: ABBV's earnings (4.3% per year) are forecast to grow slower than the US market (13% per year).

High Growth Earnings: ABBV's earnings are forecast to grow, but not significantly.

Revenue vs Market: ABBV's revenue (0.5% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: ABBV's revenue (0.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABBV's Return on Equity is forecast to be very high in 3 years time (95.7%).

Past Performance

How has AbbVie performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ABBV has a large one-off loss of $10.7B impacting its September 30 2021 financial results.

Growing Profit Margin: ABBV's current net profit margins (13.5%) are lower than last year (18%).

Past Earnings Growth Analysis

Earnings Trend: ABBV's earnings have grown by 0.9% per year over the past 5 years.

Accelerating Growth: ABBV's earnings growth over the past year (1.9%) exceeds its 5-year average (0.9% per year).

Earnings vs Industry: ABBV earnings growth over the past year (1.9%) underperformed the Biotechs industry 11%.

Return on Equity

High ROE: Whilst ABBV's Return on Equity (55.55%) is outstanding, this metric is skewed due to their high level of debt.

Financial Health

How is AbbVie's financial position?

Financial Position Analysis

Short Term Liabilities: ABBV's short term assets ($29.0B) exceed its short term liabilities ($28.5B).

Long Term Liabilities: ABBV's short term assets ($29.0B) do not cover its long term liabilities ($106.7B).

Debt to Equity History and Analysis

Debt Level: ABBV's net debt to equity ratio (504.4%) is considered high.

Reducing Debt: ABBV's debt to equity ratio has increased from 578.5% to 594.7% over the past 5 years.

Debt Coverage: ABBV's debt is well covered by operating cash flow (27.9%).

Interest Coverage: ABBV's interest payments on its debt are well covered by EBIT (8.3x coverage).

Balance Sheet


What is AbbVie current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ABBV's dividend (4.17%) is higher than the bottom 25% of dividend payers in the US market (1.35%).

High Dividend: ABBV's dividend (4.17%) is in the top 25% of dividend payers in the US market (3.48%)

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, ABBV has been paying a dividend for less than 10 years.

Growing Dividend: ABBV's dividend payments have increased, but the company has only paid a dividend for 9 years.

Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (123.2%), ABBV's dividend payments are not well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: ABBV's dividends in 3 years are forecast to be covered by earnings (50.8% payout ratio).

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Rick Gonzalez (67 yo)





Mr. Richard A. Gonzalez, also known as Rick, serves as the Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of...

CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD24.01M) is above average for companies of similar size in the US market ($USD11.29M).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: ABBV's management team is considered experienced (3.2 years average tenure).

Board Members

Experienced Board: ABBV's board of directors are considered experienced (9 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: ABBV insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

AbbVie Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: AbbVie Inc.
  • Ticker: ABBV
  • Exchange: NYSE
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$239.035b
  • Shares outstanding: 1.77b
  • Website:

Number of Employees


  • AbbVie Inc.
  • 1 North Waukegan Road
  • North Chicago
  • Illinois
  • 60064-6400
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:47
End of Day Share Price2022/01/19 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.